Global pharmaceutical companies continue to undergo significant leadership changes and strategic restructurings. GSK announced the departure of CEO Emma Walmsley, marking the end of her nine-year tenure and paving the way for internally promoted successor Luke Miels. AnaptysBio revealed plans to split into two publicly traded entities separating its pipeline and royalty assets to align investor interests. Genmab’s acquisition of Merus for $8 billion highlights active M&A in oncology. Several companies including Revolution Medicines and Climb Bio strengthened leadership teams and advanced clinical programs. These moves influence innovation trajectories and market dynamics in the biotech landscape.